We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alcon (ALC) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Read MoreHide Full Article
The upcoming report from Alcon (ALC - Free Report) is expected to reveal quarterly earnings of $0.77 per share, indicating an increase of 1.3% compared to the year-ago period. Analysts forecast revenues of $2.77 billion, representing an increase of 7.3% year over year.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
That said, let's delve into the average estimates of some Alcon metrics that Wall Street analysts commonly model and monitor.
It is projected by analysts that the 'Net Sales- Total Surgical' will reach $1.55 billion. The estimate indicates a change of +6.7% from the prior-year quarter.
The consensus among analysts is that 'Net Sales- Total Vision care' will reach $1.21 billion. The estimate points to a change of +7.5% from the year-ago quarter.
Analysts forecast 'Net Sales- Total Surgical- Consumables' to reach $822.67 million. The estimate suggests a change of +5.9% year over year.
Based on the collective assessment of analysts, 'Net Sales and other revenues- Other revenues' should arrive at $18.82 million. The estimate indicates a year-over-year change of -1%.
The collective assessment of analysts points to an estimated 'Net Sales- Total Vision Care- Contact lenses' of $726.96 million. The estimate suggests a change of +5.1% year over year.
According to the collective judgment of analysts, 'Net Sales- Total Vision Care- Ocular health' should come in at $479.63 million. The estimate suggests a change of +11.5% year over year.
The consensus estimate for 'Net Sales- Total Surgical- Implantables' stands at $463.72 million. The estimate points to a change of +1.7% from the year-ago quarter.
Analysts expect 'Net Sales- Total Surgical- Equipment/other' to come in at $266.86 million. The estimate indicates a year-over-year change of +20.2%.
Over the past month, Alcon shares have recorded returns of +6.2% versus the Zacks S&P 500 composite's +3.5% change. Based on its Zacks Rank #3 (Hold), ALC will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Alcon (ALC) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
The upcoming report from Alcon (ALC - Free Report) is expected to reveal quarterly earnings of $0.77 per share, indicating an increase of 1.3% compared to the year-ago period. Analysts forecast revenues of $2.77 billion, representing an increase of 7.3% year over year.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
That said, let's delve into the average estimates of some Alcon metrics that Wall Street analysts commonly model and monitor.
It is projected by analysts that the 'Net Sales- Total Surgical' will reach $1.55 billion. The estimate indicates a change of +6.7% from the prior-year quarter.
The consensus among analysts is that 'Net Sales- Total Vision care' will reach $1.21 billion. The estimate points to a change of +7.5% from the year-ago quarter.
Analysts forecast 'Net Sales- Total Surgical- Consumables' to reach $822.67 million. The estimate suggests a change of +5.9% year over year.
Based on the collective assessment of analysts, 'Net Sales and other revenues- Other revenues' should arrive at $18.82 million. The estimate indicates a year-over-year change of -1%.
The collective assessment of analysts points to an estimated 'Net Sales- Total Vision Care- Contact lenses' of $726.96 million. The estimate suggests a change of +5.1% year over year.
According to the collective judgment of analysts, 'Net Sales- Total Vision Care- Ocular health' should come in at $479.63 million. The estimate suggests a change of +11.5% year over year.
The consensus estimate for 'Net Sales- Total Surgical- Implantables' stands at $463.72 million. The estimate points to a change of +1.7% from the year-ago quarter.
Analysts expect 'Net Sales- Total Surgical- Equipment/other' to come in at $266.86 million. The estimate indicates a year-over-year change of +20.2%.
View all Key Company Metrics for Alcon here>>>Over the past month, Alcon shares have recorded returns of +6.2% versus the Zacks S&P 500 composite's +3.5% change. Based on its Zacks Rank #3 (Hold), ALC will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .